Palvella Therapeutics (NASDAQ:PVLA) Receives “Buy” Rating from BTIG Research

BTIG Research reiterated their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research note released on Friday morning,Benzinga reports. BTIG Research currently has a $192.00 price objective on the stock.

Several other equities research analysts also recently issued reports on the company. UBS Group reiterated a “buy” rating and issued a $143.00 price objective on shares of Palvella Therapeutics in a report on Monday, December 15th. Canaccord Genuity Group lifted their target price on Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. HC Wainwright set a $200.00 price target on shares of Palvella Therapeutics and gave the stock a “buy” rating in a research note on Monday, December 15th. Craig Hallum assumed coverage on shares of Palvella Therapeutics in a research report on Thursday, December 4th. They set a “buy” rating and a $175.00 price target on the stock. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $193.00 price objective on shares of Palvella Therapeutics in a report on Tuesday, December 16th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Palvella Therapeutics currently has an average rating of “Buy” and a consensus target price of $158.69.

Palvella Therapeutics Stock Performance

Shares of PVLA stock opened at $99.73 on Friday. The firm has a market cap of $1.18 billion, a P/E ratio of -37.92 and a beta of -0.16. The firm’s 50 day moving average price is $96.06 and its 200-day moving average price is $67.95. Palvella Therapeutics has a one year low of $12.10 and a one year high of $114.69.

Palvella Therapeutics (NASDAQ:PVLA) last posted its earnings results on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.18). As a group, research analysts predict that Palvella Therapeutics will post -3.69 EPS for the current fiscal year.

Insider Activity at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $96.47, for a total value of $415,013.94. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of PVLA. SG Americas Securities LLC acquired a new stake in Palvella Therapeutics in the fourth quarter valued at $281,000. JPMorgan Chase & Co. boosted its position in shares of Palvella Therapeutics by 33.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,338 shares of the company’s stock worth $272,000 after acquiring an additional 1,093 shares in the last quarter. Summit Partners Public Asset Management LLC purchased a new position in shares of Palvella Therapeutics in the 3rd quarter valued at about $2,188,000. Mariner LLC acquired a new stake in shares of Palvella Therapeutics during the 3rd quarter worth about $1,299,000. Finally, Fred Alger Management LLC lifted its stake in Palvella Therapeutics by 1,279.1% during the third quarter. Fred Alger Management LLC now owns 186,751 shares of the company’s stock worth $11,707,000 after purchasing an additional 173,209 shares during the last quarter. Institutional investors and hedge funds own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.